drugset
drugset / Trial / NCT06687174

Study to Evaluate the Efficacy and Safety of MY008211A in Subjects with Primary Immunoglobulin a Nephropathy (IgAN)

NCT06687174 ↗

Phase 2 Not yet recruiting 72 enrolled Wuhan Createrna Science and Technology Co., Ltd
RandomizedParallel-groupTriple-blindTreatment

Summary

Efficacy and safety of MY008211A in IgAN patients

Timeline

Start
2024-12-31
Primary completion
2026-06-15
Completion
2028-01-31

Drugs

EvaluationDrugModalityDoseRoute
Subject MY008211A Unknown 200 mg —
Subject MY008211A Unknown 400 mg —

Indications

IgA glomerulonephritis